Santirol

The therapeutic efficacy of dexamethasone + neomycin + polymyxin B stems from the synergistic actions of its three active components. Dexamethasone, a potent synthetic corticosteroid, exerts its anti-inflammatory effects by inhibiting the release of various inflammatory mediators, including prostaglandins and leukotrienes. It also stabilizes lysosomal membranes, reduces capillary permeability, and suppresses leukocyte migration and phagocytosis, thereby diminishing the inflammatory response, reducing edema, redness, and pain in the affected tissue. Neomycin is an aminoglycoside antibiotic that primarily works by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and leading to bacterial cell death. It provides coverage against a range of Gram-negative and some Gram-positive bacteria. Polymyxin B, a cyclic polypeptide antibiotic, acts by disrupting the integrity of the bacterial cell membrane. It interacts with the phospholipids of the bacterial outer membrane, increasing its permeability and leading to the leakage of essential intracellular components, ultimately causing bacterial lysis. Polymyxin B is particularly effective against Gram-negative organisms, including *Pseudomonas aeruginosa*. This multi-component approach ensures both broad-spectrum antibacterial coverage and comprehensive inflammation control, making it effective against mixed infections and inflammatory conditions with bacterial involvement.